Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Search Results to Slide Tray Search:

"mechanism of action"

Slides: 1–11 of 11
Add to tray Remove from tray

Background: Glucosamine and Chondroitin

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: chondroitin | glucosamine | background
When Analytic Frameworks Are Developed. Analytic frameworks are developed during the writing phase, at the end of the systematic review. A. True. B. False.
Add to tray Remove from tray

When Analytic Frameworks Are Developed

Presentation: Analytic Frameworks Quiz
The Coagulation Cascade: rFVIIa Mechanism of Action Recombinant activated factor VII is a form of human factor VII produced by recombinant technology. The molecule is 406 amino acids in length and has a molecular weight of 50 kDa. As a protein-based therapy, it must be given intravenously to facilitate coagulation at sites of bleeding and has a half-life of 2.5 hours. This intravenously delivered product works as a potent procoagulant by effectively bypassing parts of the clotting process normally required for clotting. rFVIIa helps to promote clotting in two ways: At physiologic levels and in association with tissue factor (e.g., on damaged tissue), it activates factors IX and X to initiate the clotting leading to formation of a thrombin plug, which allows for clot stability. This normal physiological mechanism suggests that rFVIIa activity is targeted to areas of tissue damage. In pharmacological doses, it also binds to activated platelets and drives the process of thrombin clot formation forward via factor X activation, even in the absence of tissue factor. This mechanism is relatively specific to areas of tissue damage. These mechanisms effectively bypass portions of the clotting process that are normally required for clotting to occur. Thus, clotting can occur despite factor deficiencies (in factors VII, VIII, IX, and XI) or when the number or function of platelets is reduced. It can facilitate control of bleeding in situations where standard human blood product transfusions have failed. While mainly used for hemophilia and related conditions, off-label use of rFVIIa has increased in the hospital setting. Practice patterns have outstripped available evidence as rFVIIa off-label use has transitioned from extraordinarily infrequent use to more common application.
Add to tray Remove from tray

The Coagulation Cascade: rFVIIa Mechanism of Action

Presentation: Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Keywords: coagulation cascade | mechanism of action | recombinant factor VIIa
Add to tray Remove from tray

Causal Models and the Structural Relationship of Variables (3 of 7)

Presentation: Covariate Selection for Observational Comparative Effectiveness Research
Keywords: causal models | intermediate variables
Add to tray Remove from tray

DMARDs for Treating JIA (1 of 2)

Presentation: Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
Add to tray Remove from tray

DMARDs in Rheumatoid Arthritis Treatment (2 of 2)

Presentation: Drug Therapy for Rheumatoid Arthritis in Adults
Keywords: rheumatoid arthritis | RA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | oral | cytokines | TNF-alpha | tumor necrosis factor-alpha | interleukin 1 | IL-1 | interleukin 6 | IL-6 | CD20 | CD28
Add to tray Remove from tray

Introduction to Antipsychotics in Pediatric Use (1 of 4)

Presentation: First- and Second-Generation Antipsychotics for Children and Young Adults
Keywords: antipsychotics | pediatrics | first-generation antipsychotics | second-generation antipsychotics | typical antipsychotics | atypical antipsychotics
Add to tray Remove from tray

Management of an Adult With Type 2 Diabetes With Antidiabetic Medications: A Case Scenario

Presentation: Management of an Adult With Type 2 Diabetes With Antidiabetic Medications: A Case Scenario
Keywords: adverse effects | antidiabetic medications | benefits | hyperglycemia | macrovascular outcomes | microvascular outcomes | type 2 diabetes | case study
Add to tray Remove from tray

Clinical Outcomes (2 of 2)

Presentation: Outcome Definition and Measurement in Observational Comparative Effectiveness Research
Keywords: clinical outcomes | selection | interactions with healthcare system
Add to tray Remove from tray

Background: Treatment for Depression

Presentation: Second-Generation Antidepressants for Treating Adult Depression—An Update
Keywords: treatment | depressive disorders | pharmacotherapy | second-generation antidepressants
Add to tray Remove from tray

Second-Generation Antidepressants Included in the 2011 Updated Review

Presentation: Second-Generation Antidepressants for Treating Adult Depression—An Update
Keywords: second-generation antidepressant | selective serotonin reuptake inhibitor | serotonin and norepinephrine reuptake inhibitor | selective serotonin and norepinephrine reuptake inhibitors
 
 
 
 
www.ahrq.gov AHRQ Home | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364